Pancreatic Cancer Research

ResearcherDana-Farber Cancer InstituteNo recent work listed

Jason J. Kwon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3053-2919; OpenAlex author ID A5044564218; NIH RePORTER profile ID 12043428. Sources: OpenAlex.

Their work

Papers
5 (first author 2, last author 0)
Trials
0
Grants
2
Labs led
0
Collaborators
7
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper, 1 grant · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 grant

Papers 5

  1. miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2. First author DOI 10.1158/1541-7786.mcr-19-0594↗
  2. Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. First author DOI 10.1016/j.omtm.2017.09.006↗
  3. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Co-author DOI 10.1016/j.canlet.2016.12.035↗
  4. Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Co-author DOI 10.18632/oncotarget.11928↗
  5. Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Co-author DOI 10.1038/srep11450↗

Grants 2

  1. Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer F32CA243290↗
  2. Pathophysiological role and therapeutic potential of microRNA-29 in pancreatic cancer autophagy F31CA213731↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Janaiah Kota · 5 shared papers, 2015–2020 · strength 0.40
  2. Murray Korc · 4 shared papers, 2015–2018 · strength 0.28
  3. Kayla A. Quirin · 2 shared papers, 2016–2018 · strength 0.14
  4. Shatovisha Dey · 1 shared paper, 2020 · strength 0.12
  5. Teresa A Zimmers · 1 shared paper, 2020 · strength 0.12
  6. Joshua T Mendell · 1 shared paper, 2018 · strength 0.07
  7. Jesse Gore · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.